2022 American Transplant Congress
Tolerant B Cells Suppress Memory B Cells in a Donor Specific Manner in CoB Mediated Transplantation Tolerance
*Purpose: We previously reported that B cells in recipients made tolerant to fully mismatched heart allografts by anti-CD154+donor spleen cells (CoB) become dysfunctional in their…2022 American Transplant Congress
Donor-Specificb Cell Dysfunction and Suppressive Ability Are Differentially Induced in Cob-Mediated Transplantation Tolerance
*Purpose: B cells in mice tolerized to fully mismatched heart allografts with anti-CD154+donor spleen cells (CoB) are intrinsically dysfunctional and unable to differentiate into germinal…2022 American Transplant Congress
Belatacept Augments Mixed Chimerism in a Novel Nonhuman Primate Kidney Transplant Tolerance Induction Protocol
University of Wisconsin, Madison, WI
*Purpose: A novel protocol of antilymphocyte globulin (ATG), tomotherapy-based total lymphoid irradiation (TomoTLI), and adoptive cellular transfer was developed in a preclinical model of MHC-mismatched…2022 American Transplant Congress
Five-Year Follow-Up from a Prospective, Randomized Trial of Belatacept-Based, CNI Free/Early Steroid Withdrawal Regimens
1University of Cincinnati, Cincinnati, OH, 2Christ Hospital, Cincinnati, OH
*Purpose: A prospective, randomized, multi-center trial designed to compare two belatacept (BELA)-based, calcineurin inhibitor-free (CNI), early corticosteroid withdrawal (ESW) regimens with a tacrolimus (TAC)-based ESW…2022 American Transplant Congress
Validation of the iBox Surrogate End Point in CNI Free, Belatacept Treated Patients (BENEFIT & BENEFIT-EXT)
*Purpose: The iBox is a prognostication system for long-term kidney allograft survival, developed with mostly patients under a CNI based immunosuppression. Patients treated with a…2022 American Transplant Congress
Long-Term Outcomes After Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant: A Matched Cohort Study
Paris Transplant Group, INSERM, Paris, France
*Purpose: Conversion to belatacept after transplant seems to be safe. However, no studies have reported the long-term efficacy and safety outcomes after conversion to belatacept…2022 American Transplant Congress
CD8+ T Cells Differentiate into a CD43-expressing Effector Population After Transplantation
Department of Pathology, Johns Hopkins University, Baltimore, MD
*Purpose: Despite a significantly reduced toxicity profile and improved long-term graft function versus calcineurin inhibitors, widespread adaptation of belatacept (CTLA-4 Ig) has been limited due…2022 American Transplant Congress
Conversion to Belatacept for Calcineurin Inhibitor Toxicities
Columbia University Medical Center, New York, NY
*Purpose: Calcineurin inhibitors (CNIs) have improved renal transplant (RTx) outcomes but are associated with significant toxicities. Belatacept provides better long-term outcomes than cyclosporine, has less…2022 American Transplant Congress
p40 Homodimers Stimulate Graft Dendritic Cells to Produce IL-15 Driving Endogenous Donor-Reactive Memory CD8 T Cell Activation within High-Risk Cardiac Allografts
*Purpose: Acute allograft injury occurring during the first 1-2 days post-transplant is mediated by graft infiltrating endogenous donor-reactive memory CD8 T cells and requires their…2022 American Transplant Congress
Desensitization Using Costimulatory Blockade and Bortezomib to Prevent DSA Formation and Rejection in Reconstructive Transplantation
Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: Sensitization in form of donor-specific antibodies (DSA) and subsequent antibody-mediated rejection constitute some of the greatest risk factors for allograft rejection and long-term graft…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 30
- Next Page »